We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Loses Appeal of Claim that Viatris Monopolizes EpiPen Market
Sanofi Loses Appeal of Claim that Viatris Monopolizes EpiPen Market
Sanofi has failed to convince a federal appeals court that Viatris (formerly Mylan) monopolized the market for epinephrine auto-injectors through anticompetitive pricing for its EpiPen.